Overview

Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours

Status:
Completed

Trial end date:
2018-02-01

Target enrollment:

Participant gender:

Summary

Treating patients with initial local non-resectable pancreatic cancer with a combination of oxaliplatin, irinotecan & 5-FU(FOLFIRINOX), consolidated with chemoradiotherapy in potentially resectable patients, will result in a high rate of tumor shrinkage allowing subsequent resection in patients with initial borderline resectable tumors and improved overall survival for all patients.

Phase:

Phase 2

Details

Lead Sponsor:

Per Pfeiffer

Treatments:

Irinotecan
Leucovorin
Oxaliplatin